Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. - Wikidata - wikimedia - TriplyDB

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

http://www.wikidata.org/entity/Q54299156

about

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.Effects of Specialty Pharmacy Care on Health Outcomes in Multiple Sclerosis Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.Knowledge and attitude assessment of Iranian multiple sclerosis patients receiving interferon beta Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis Improving patient-physician dialog: commentary on the results of the MS Choices survey.Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol.Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment.Hospitalization rates and discharge status in multiple sclerosis Health insurance affects the use of disease-modifying therapy in multiple sclerosis.ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.Facilitating medication adherence in patients with multiple sclerosis.An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.Patient expectations and experiences of multiple sclerosis interferon β-1a treatment: a longitudinal, observational study in routine UK clinical practice.Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis.Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis.

P2860

Q22252598-E5E4E485-25C0-4A4D-BAFE-9862C72E2A17 Q27015089-81659151-3CCC-450B-AAFD-7A367DCD6C92 Q28066677-4845F2BD-F3A9-49D3-9E70-1DE8DF312B30 Q28081876-C8309B59-C8DC-4D86-A384-4F5D8CB1657B Q30830291-DA3584E0-F863-4665-A107-96075EFE1ABE Q30834523-8A51C046-CB24-4F9E-ACB6-EF272382794D Q30839407-BFDBFC49-2FC9-4E74-9C47-4C22B327AE1C Q33572798-FCA3B857-7F37-4DA5-91DC-23B7F5ACAF2A Q33610126-C6CAAF0E-ABD5-4721-B6A1-81A504982111 Q33638157-17AAE99D-A9BA-4885-B6BC-47A7D2E048B6 Q33692801-A0D8FD1A-4542-471C-ADEC-C82A2D3E1A44 Q33764067-963D3378-F9BA-486E-9859-B6A600570A09 Q33878804-2DF9C35A-7D06-4256-8905-B916B1B26BB4 Q34473419-8422F124-93CF-48AB-AFD6-7039FFDB405F Q34558986-9C1511FE-2145-40D9-AA9D-0201FFCC3CD3 Q35007948-D5264E63-B31B-4582-8514-F3E9CFD8F32A Q35091777-5DC046C1-E8CF-49E0-953C-A7EC01A1FE71 Q35103997-34562C34-2ECB-4835-8356-B55D6A7DE7D4 Q35659134-54E1BBDE-A71F-41AB-B2C8-CB5F42D9B4F0 Q35674845-27DBB3FD-3CCA-4B4D-BA00-280DDF6B9ADC Q35780959-B8CF4136-6261-4CB6-9C1C-6CC91C56F848 Q35784295-FBE23D93-F923-4FB3-8EBD-0BE3096D3363 Q35948187-9D053E99-ABC2-44EA-A92F-0337452FC21C Q36125599-B5BB7CC3-02A7-42EC-9BA9-93C2750416E1 Q36182036-66D0BA94-8384-440A-9272-49936E0A87D6 Q36223650-DFC16944-1A15-453A-9A25-B625169C6A2E Q36393288-E0D9DBBF-B956-4416-AF44-58C3B6A8C6B7 Q36595213-5A140BD2-3009-4DFF-9D37-3514C0846613 Q36698871-84579461-4079-468D-9015-044E43387671 Q36861884-F533086A-82AF-4796-B86C-6DAB2EDFD0A3 Q36882707-17015F42-2922-48E4-9592-0609C58F76AC Q37158954-33CF739A-07EB-4928-BE87-7090872DBEE6 Q37320927-D1C8EA34-E5BC-4582-94C1-5F91FE4677C8 Q37442437-9917C760-2DA3-4559-B1CF-1036213075B9 Q37573148-EB686EBB-C8AD-4086-B99F-5367B978049E Q37601305-08D993F9-7C68-4F94-9FC3-CA620EC61CD2 Q37668556-3584B2E8-AB24-458B-9418-071D04390CF8 Q37682836-F0970946-3B93-4DAA-829B-69A979D969BA Q37684523-87F53E00-93BA-44BA-BD5C-C89620D283BF Q37987991-4693817C-2246-418C-A218-C1193B86D321

P2860

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

http://www.wikidata.org/entity/Q54299156

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Impact of adherence to disease ...... ients with multiple sclerosis.

@en

Impact of adherence to disease ...... ients with multiple sclerosis.

@nl

type

label

Impact of adherence to disease ...... ients with multiple sclerosis.

@en

Impact of adherence to disease ...... ients with multiple sclerosis.

@nl

prefLabel

Impact of adherence to disease ...... ients with multiple sclerosis.

@en

Impact of adherence to disease ...... ients with multiple sclerosis.

@nl

P1433

Q54299156-95CF0430-3EA7-4BFA-AD4F-DC77363640EE

P1476

Q54299156-ADB87F7F-C328-4291-9005-4D5857019631

P2093

Q54299156-0286DAEB-95A0-42A8-B43A-0F41AE8F8BBD

Q54299156-1E33E33E-FDED-4C69-9B09-C1282572EB49

Q54299156-233A52E0-2B93-4559-8C98-86648A7D13BF

Q54299156-7CF77D29-8DFB-46E3-9FD2-D93B77F77575

Q54299156-EE0CE0BA-889F-407B-A1C0-08BBF0F3BCDC

P2860

Q54299156-0C1BEFE4-534B-4633-9880-C0C5A12E28A6

Q54299156-12783FCE-9077-476B-AA98-67C40016A890

Q54299156-1622B973-30B5-4972-8034-7D8CB3DED41E

Q54299156-1746A871-79C0-42E2-B928-B738F31E5590

Q54299156-24ED8AB0-52E7-4E38-B05A-B8038457CA63

Q54299156-4DF5A926-C1DB-4CBC-8D21-B7B92734468A

Q54299156-59E96FEC-E62D-4AAA-81D7-9CEBA29200A7

Q54299156-5CE11568-0478-4A00-BBEE-6093F0E7BB9D

Q54299156-61271A04-A055-4E7C-9754-32D9694D2B35

Q54299156-6A124E9A-8102-4484-A172-0D61DE9BE917

P2888

Q54299156-B568B72F-A1D1-44B8-B8AD-9E77B4D6BC84

P304

Q54299156-5C015796-8FAE-49DB-BE7B-F3457170F4BD

P31

Q54299156-4E52EEA6-DA9A-4240-A713-E2600473EF13

P356

Q54299156-F5AE9D25-9114-41BB-9F70-5A5F9E9A12FA

P407

Q54299156-3D7EBFE0-9BB8-4BC0-9DD3-C58264AAE58E

P433

Q54299156-702F4BFC-21A1-4F14-ABD8-DDB789FC92F1

P478

Q54299156-BE26FBA5-7D63-4083-8155-5736841E7F5A

P577

Q54299156-969AC0CC-0079-488F-8D25-8597C84A6281

P5875

Q54299156-6EF41861-CF74-4B21-8E26-99EE1DAD2EF7

P698

Q54299156-34B66953-97C9-46CF-B240-89E2B45F12B7

P921

Q54299156-0BB4DCDE-57C5-4BBB-B78E-1DDA71D9C5CD

P356

S12325-010-0093-7

P1433

Advances in Therapy

P1476

Impact of adherence to disease ...... ients with multiple sclerosis.

@en

P2093

Hiangkiat Tan

http://www.w3.org/2001/XMLSchema#string

Judith J Stephenson

http://www.w3.org/2001/XMLSchema#string

Qian Cai

http://www.w3.org/2001/XMLSchema#string

Siddhesh Kamat

http://www.w3.org/2001/XMLSchema#string

Sonalee Agarwal

http://www.w3.org/2001/XMLSchema#string

P2860

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Adherence to Medication

Multiple sclerosis.

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study.

Effect of relapses on development of residual deficit in multiple sclerosis.

Early intervention in multiple sclerosis : better outcomes for patients and society?

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

Methods for evaluation of medication adherence and persistence using automated databases.

P2888

s12325-010-0093-7

P304

51-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-010-0093-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49678656

http://www.w3.org/2001/XMLSchema#string

P698

21153000

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis